Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age-and sex-matched healthy controls Leukemia (2004) Multiple myeloma (MM) is a malignant proliferation of plasma cells. Skeletal involvement is present at diagnosis in about 80% of cases and in almost all patients during the course of disease. Myeloma plasma cells induce bone destruction by increasing bone resorption, through the activation of osteoclasts. A number of osteoclast-activating factors (OAFs) have been identified, including tumor necrosis factor (TNF)-a and -b, interleukin (IL)-1b, IL-6, vascular endothelial growth factor (VEGF), and macrophage inflammatory protein (MIP)-1a and -b. An essential cytokine system for osteoclast biology consists of the receptor activator of NF-kB ligand (RANKL), its receptor RANK, and the soluble decoy receptor osteoprotegerin (OPG). RANKL stimulates osteoclast differentiation and activity, and inhibits osteoclast apoptosis; these actions result in enhanced bone resorption. OPG binds to RANKL and prevents RANKL/RANK interaction.
1 Myeloma plasma cells have been found to increase RANKL expression and to decrease OPG availability in the bone microenvironment, yielding an increase of the osteoclastogenic signal as a consequence of increased RANKL/OPG ratio. 1 OPG circulates in peripheral blood under various forms, in complexes with soluble RANKL besides a free, nonbound portion. The heterogeneity of these circulating forms may account for discrepancies of absolute values reported in the literature. As far as patients with MM are concerned, serum levels of OPG have been repeatedly found to be decreased with respect to healthy controls, 2,3 the levels in the blood stream were found to be correlated with those in the bone marrow plasma. 4 To the best of our knowledge, no data are available on patients with MGUS and MM as a function of treatment. The aim of the present cross-sectional study was to investigate serum levels of OPG in a large group of MGUS and MM patients and in a 1:1, sex-and age-matched population of healthy controls.
A total of 103 MM patients (66 men and 37 women) and 37 MGUS (19 men and 18 women) were included in the study. Patients were diagnosed according to the criteria by Kyle et al. In all, 140 age-and sex-matched healthy subjects (84 men and 56 women) were recruited as controls among blood donors (up to 65 years of age) and people attending a light physical training program (over 65 years of age). None of the controls were receiving medications or had medical conditions known to affect bone metabolism.
In patients with MM, the following parameters were examined: Durie and Salmon stage, clinical and/or radiological evidence of presence of bone disease, calcemia, serum b 2 -microglobulin, phase of disease (at onset or under treatment), therapy with bisphosphonates. Characteristics of MM patients were as follows: median age 57 (32-82) years; 43 patients were in stage I, 15 in stage II, and 45 in stage III; 48 showed lytic lesions; 39 patients were at onset and 64 under treatment; 32 patients were treated with pamidronate at 90 mg intravenously every 4 weeks.
Serum of all patients were drawn between 1997 and 2003 and frozen at À701C to be analyzed later. OPG serum concentrations were measured by an ELISA developed in our laboratory using commercially available reagents (OPG DuoSet, R&D Systems, Abingdon, UK), according to the manufacturer's instructions and previously published results. 5 Capture antibody was a monoclonal mouse anti-human OPG; detection antibody was a biotinylated goat polyclonal anti-human OPG. Reagent diluent was PBS with 50% FCS and 1% BSA. Analytical performance parameters were as follows: range: 62.5-4000 pg/ ml; minimum detectable concentration (measured as blank þ 3 s.d.): o30 pg/ml; intra-assay CV: o6%; interassay CV: 14.7%. Results were expressed as pg/ml.
The association of diagnosis and disease parameters and logtransformed OPG levels, while controlling for age and sex, was assessed by means of general linear models. Stata 8 (StataCorp, College Station, TC) was used for computation. A two-sided P-valueo0.05 was considered statistically significant.
OPG serum levels are reported in Table 1 . We found increased serum levels in MM and MGUS patients with respect to matched healthy controls, independently of age and sex. Moreover, we did not find any significant correlation either with the presence of osteolysis or with other disease parameters, even when considering patients at onset (Table 2) . Consistently with the present study, Kraj et al 6 have recently reported serum levels of OPG higher in MM than in healthy controls without significant correlation with the appearance of osteolysis. Taken together, these results are intriguingly at variance with those previously reported in the literature. Serum OPG was repeatedly found to be decreased in MM patients with respect to controls. Decreased serum levels were suggested to reflect decreased bone marrow levels, possibly as a consequence of plasma cell colonization and reduced OPG availability in the bone microenvironment. Moreover, serum levels of OPG were found to correlate with bone turnover markers and extent of bone disease. 2, 3 There is no obvious explanation for such discrepancies, but a number of points call for attention. Our cohort included patients both at diagnosis and under treatment, while Seidel et al and Terpos et al recruited only patients at diagnosis. Pertinently, increased levels of serum OPG are common among subjects chronically exposed to glucocorticoid excess. 5 Indeed, in our study, all patients under treatment received glucocorticoid therapy (prednisone or dexamethasone). On the other hand, we did not find significant differences of OPG serum level among myeloma patients at onset, patients under chemotherapy or bisphosphonates, and MGUS patients. Both median levels and quartiles were comparable in the three groups of MM patients and were in all cases significantly higher than in controls. Therefore, the three groups could be considered to belong to a homogeneous cohort ( Figure 1 and Table 1 ). Additionally, when analyzing disease parameters, we did not find any correlation with serum OPG in the subgroups of patients at onset or under treatment. Therefore, it is reasonable to argue that circulating immunoreactive OPG rose as a function of the underlying B-cell disease, independently of age and possibly favored by glucocorticoid mediation. Longitudinal studies in patients before and during treatment deserve 
Figure 1
Distribution of the median OPG serum values in the four groups considered. Analysis was performed on log-transformed values and significance are reported in Table 1 .
Correspondence attention. Our study was cross-sectional. The 1:1 design allowed the recruitment of a relatively large control population and the confirmation that in both sexes serum OPG normally increases while advancing age. This observation may also be viewed as a counterevidence for disease-related mechanisms accounting for higher levels in MM and MGUS patients as well. Indeed, no previous study included MGUS patients. Interestingly enough, our data do not support the view that circulating OPG reflects its availability in the bone microenvironment. It is currently agreed that OPG gene is expressed by many cell types. OPG levels may come from a number of sources. Vascular expression of OPG is a focus of intense research. Since OPG reportedly acts as an antiapoptotic factor for endothelial cells 7 and angiogenesis was found to be increased in both MGUS and MM microenvironments, increased OPG levels could reflect such processes too. Clearly, much more information on the RANKL/RANK/OPG system in tissutal compartments other than bone are needed before drawing any assumption on the relevance of serum OPG levels to lytic bone disease.
An important point concerns analytical issues. OPG is measurable by immunometric methods that provide ranges of normality remarkably different as a function of different antibody pairs and reagents and preanalytical variables as well, as we and others have previously pointed out. 8 Conceivably, different available reagents recognize different OPG forms.
In conclusion, we found increased OPG levels in both MGUS and MM patients. OPG levels did not correlate with disease stage and skeletal manifestations. Further studies are needed to define the significance of serum levels of OPG in plasma cell disorders. Given a number of unexplored analytical and preanalytical issues, and wide expression of OPG in human tissues, caution must be used in interpreting serum OPG as a marker of myeloma bone disease.
